Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer: Safety and efficacy in a real-life population

González-Flores, Encarnación; González-Astorga, Beatriz; Ureña, Teresa Delgado; Cebrián, Irene González; Sanchez-Toro, C.; Garcı́a-Garcı́a, Javier; Conde, V.

doi:10.1093/annonc/mdx261.314

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade ≥ 3 hypertension and thromboembolic events were observed in 7.2% and 6% of patients, respectively [28]. In another Spanish study, which evaluated 66 patients with mCRC who received aflibercept plus FOLFIRI, the most frequent grade 3/4 toxicities were asthenia (13%), neutropenia (11.5%), hypertension (10%), diarrhea (8%), stomatitis (3.2%), palmar-plantar erythrodysesthesia (3.2%) and proteinuria (5%) [29]. In another study evaluating 78 patients who received second-line aflibercept plus FOLFIRI, the most frequently occurring grade 3/4 toxicities were neutropenia (15.3%), asthenia (10.3%), diarrhea (6.4%) and mucositis (6.4%) [30].…”

Section: European and The Us Studiesmentioning

confidence: 99%

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Muro

Salinardi

Singh

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations.

show abstract

Section: European and The Us Studiesmentioning

confidence: 99%

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Muro

Salinardi

Singh

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

2021

View full text Add to dashboard Cite

Targeting tumor-driven angiogenesis is an effective strategy in the management of metastatic colorectal cancer (mCRC); however, the choice of second-line therapy is complicated by the availability of several drugs, the occurrence of resistance and the lack of validated prognostic and predictive biomarkers. This review examines the use of angiogenesis-targeted therapies for the second-line management of mCRC patients. Mechanisms of resistance and anti-placental growth factor agents are discussed, and the role of aflibercept, a recombinant fusion protein consisting of portions of human vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2, is highlighted. The novel mechanism of action of aflibercept makes it a useful second-line agent in mCRC patients progressing after oxaliplatin-based chemotherapy, as well as in those with resistance after bevacizumab.

show abstract

Experience with aflibercept as a second line chemotherapy in metastatic colorectal cancer: Safety and efficacy in a real-life population

Cited by 2 publications

References 0 publications

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

Contact Info

Product

Resources

About